InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,297.62
(
0.01%
)
US TECH 100
18,096.80
(
0.10%
)
Dow Jones
39,895.07
(
0.06%
)
Brent Oil
83.31
(
0.12%
)
Bitcoin
66,787.90
(
2.37%
)
Post# of 251845
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119654
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Double_Bagel post# 197589

Monday, 11/23/2015 3:03:33 PM

Monday, November 23, 2015 3:03:33 PM

Post# of 251845

Barclays sets CHRS target value at $46 ($1.8 Billion valuation) and MNTA target value at $22 ($1.5 Billion valuation). So, he gives almost no credit for MNTA's biosimilar platform.

Leaving MNTA aside, for the sake of discussion, the Barclays analyst is apparently ignoring the red flags wrt the bioequivalence study for CHRS' Neulasta FoB: #msg-117420090, #msg-117407131.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up